Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic cancer after previous gemcitabine-based therapy: a randomised, double-blind, parallel-controlled, multicentre phase 3 trial
| Title | Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic cancer after previous gemcitabine-based therapy: a randomised, double-blind, parallel-controlled, multicentre phase 3 trial |
|---|---|
| Description | Liposomal irinotecan has shown promising antitumour activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma who have been treated with gemcitabine-based therapies. This phase 3 trial assessed the efficacy and safety of a novel liposomal irinotecan HR070803 in combination with 5-fluorouracil and leucovorin in this population. |
| Organism | Homo sapiens |
| Data Type | Clinical Research data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA017910 |
| Release Date | 2023-12-31 |
| Submitter | binbin liu (binbin.liu@hengrui.com) |
| Organization | Jiangsu Hengrui Pharmaceutical Co., Ltd |
| Submission Date | 2023-06-28 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX004438-01 | Clinical data | 1 | Clinical Research data | 314.4 KB | 0 | Controlled |